Androgen therapy: Testing before prescribing and monitoring during therapy

Canadian Family Physician

Volumn 53, Issue 11, 2007, Pages 1936-1942

  Katz, Alan ^a,b,c   Katz, Anne ^c   Burchill, Charles ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c Cancer Care Manitoba ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE UNDECANOATE;

ADOLESCENT; ADULT; AGED; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; TESTOSTERONE BLOOD LEVEL; AGE; BLOOD; BLOOD ANALYSIS; CANADA; DRUG EFFECT; DRUG UTILIZATION; FOLLOW UP; GENERAL PRACTICE; HORMONE SUBSTITUTION; METABOLISM; METHODOLOGY; MIDDLE AGED; MONITORING; PATHOPHYSIOLOGY; PROSTATE; PROSTATE TUMOR; RETROSPECTIVE STUDY; RISK FACTOR;

AGE FACTORS; AGED; BLOOD CHEMICAL ANALYSIS; COHORT STUDIES; DRUG UTILIZATION; FAMILY PRACTICE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MANITOBA; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TESTOSTERONE;

EID: 38449106536     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. IMS Health Inc. IMS sales data 2001. Westport, CT: IMS Health Inc; 2001.
2. Juul A, Skakkeback N. Androgens and the aging male. Hum Reprod Update 2002;8(5):423-33.
3. Moncada I. Testosterone and men's quality of life. Aging Male 2006;9(4):189-93.
4. Tenover J. Tetosterone replacement therapy in older men. Int J Androl 1999;22:300-6.
5. Nolten W. Androgen deficiency in the aging male: when to evaluate and when to treat. Curr Urol Rep 2000;1:313-9.
6. Morales A, Bain J, Ruijs A, Chapdelaine A, Tremblay R. Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation. Int J Impot Res 1996;8:95-7.
7. Guay AT, Perez J, Fitaihi W, Vereb M. Testosterone treatment in hypogonadal men: prostate specific antigen level and risk of prostate cancer. Endocr Pract 2000;6(2):132-8.
8. Partin A, Hanks G, Klein E, Moul J, Nelson W, Scher H. Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology 2002;16(8):1024-47.
9. Kozyrskyj A, Mustard C. Validation of an electronic population-based prescription database. Ann Pharmacother 1998;32:1152-7.
10. Roos L, Walld R, Wajda A, Bond R, Hartford K. Record linkage strategies, outpatient procedures and administrative data. Med Care 1996;34(6):570-82.
11. Frolich N, Fransoo R, Roos N. Health service use in the Winnipeg Regional Health Authority: variations across areas in relation to health and socioeconomic status. Healthc Manage Forum 2002;Winter;Suppl:9-14.
12. Morley J, Perry H III. Androgen treatment of male hypogonadism in older males. J Steroid Biochem Mol Biol 2003;85:367-73.
13. Rolf C, Nieschlag E. Potential adverse effects of long-term testosterone therapy. Bailliere's Clin Endocrinol Metab 1998;12(3):521-34.
14. Morales A. Androgen replacement therapy and prostate safety. Eur Urol 2002;41:113-20.
15. Slater S, Oliver R. Testosterone: its role in development of prostate cancer and potential risk from use as a hormone replacement therapy. Drugs Aging 2000;17(6):431-9.
16. Hajjar R, Kaiser F, Morely J. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrosepctive analysis. J Clin Endocrinol Metab 1997;82(11):3793-6.
17. Snyder P, Peachey H, Berlin J, Hannoush P, Hadda G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85(8):2670-7.
18. Gerstenbluth R, Maniam P, Corty E, Seftel A. Prostate specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002;23(6):922-6.
19. Sih B, Morley J, Kaiser F, Perry H, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997;82(6):1661-7.
20. Svetec DA, Canby ED, Thompson IM, Sabanegh ES Jr. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol 1997;158(5):1775-7.
21. Kenny AM, Prestwood KM, Raisz LG. Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels. Endocr Res 2000;26(2):153-68.
22. Gaylis F, Lin D, Ignatoff J, Amling C, Tutrone R, Cosgrove D. Prostate cancer in men using testosterone supplementation. J Urol 2005;174(2):534-8.
23. Roos L, Mustard C, Nicol J, McLerran D, Majenka D, Young T. Registration and administrative data: organization and accuracy. Med Care 1993;31(3):201-12.
24. Pommerville PJ. Andropause: knowledge and awareness among primary care physicians in Victoria, BC, Canada. Aging Male 2006;9(4):215-20.
25. Gutknecht D. Evidence-based advertising? A survey of four major journals. J Am Board Fam Pract 2001;14(3):197-200.